• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Eligard (leuprolide acetate) injectable suspension

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – April 2011

Summary View

 

5 WARNINGS AND PRECAUTIONS

5.4 Cardiovascular diseases:
  • Increased risk of myocardial infarction, sudden cardiac death and stroke has been reported in men ( added). Monitor for cardiovascular disease and manage according to current clinical practice.